Brief: Cyclo Therapeutics Announces First Patient Dosed In Phase 2B Study Of Trappsol® Cyclo™ For The Treatment Of Early Alzheimer’S Disease
09/01/2023 13:36
Jan 9 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
2B
STUDY OF TRAPPSOL® CYCLO™ FOR THE TREATMENT OF EARLY ALZHEIMER’S
DISEASE
Source text for Eikon: ID:nBw3MqwDda
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug